Tag: convalescent plasma

1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual care). 2. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Convalescent plasma is a...
1. Transfusion of high-titer convalescent antibody plasma was associated with a lower risk of death from coronavirus disease 2019 (COVID-19), compared to low-titered transfusions. 2. The mortality benefit of convalescent plasma antibodies was only observed in patients during earlier stages of the disease. Evidence Rating Level: 2 (Good) Study Rundown: During the current...
1. Transfusion of high-titer convalescent antibody plasma was associated with a lower risk of death from coronavirus disease 2019 (COVID-19), compared to low-titered transfusions. 2. The mortality benefit of convalescent plasma antibodies was only observed in patients during earlier stages of the disease. Evidence Rating Level: 2 (Good) Study Rundown: During the...
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression. 2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. Patients aged 65 years or greater who received convalescent plasma within 72 hours of symptom onset were less likely to develop severe respiratory disease compared to those who received placebo. 2. These benefits appeared to be dose-dependent, with higher donor antibody concentrations conferring greater protection upon the recipients. Evidence Rating...
1. Convalescent plasma did not improve clinical outcomes in patients with severe pneumonia due to coronavirus disease 2019 (Covid-19) compared to placebo. 2. Convalescent plasma did not reduce 30-day mortality in patients with Covid-19 compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment of convalescent plasma is guided by...
1. In this small, uncontrolled, non-randomized case series, clinical improvement was noted in 5 critically ill patients with COVID-19 and ARDS following treatment with convalescent plasma. Evidence Rating: 4 (Below Average) With no specific therapeutic agents or vaccines available for COVID-19, ongoing efforts are being made to identify a treatment option...
1. In this small, uncontrolled, non-randomized case series, clinical improvement was noted in 5 critically ill patients with COVID-19 and ARDS following treatment with convalescent plasma. Evidence Rating: 4 (Below Average) With no specific therapeutic agents or vaccines available for COVID-19, ongoing efforts are being made to identify a treatment option...